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Objectives
• Review the history and development of oral oncolytics
• Compare and contrast the differences between oral 
and parenteral chemotherapy
• Understand the most common misconceptions of oral 
oncolytics
• Review the pharmacy practice standard for oral 
oncolytic therapy developed by the 
Hematology/Oncology Pharmacy Association (HOPA)
• Highlight some of the recently approved oral 
oncolytics and review their indication, adverse effects, 
and place in therapy
Definitions
NCI Dictionary of Cancer Terms
Introduction
• Oral oncolytics are a broad pharmacologic class 
made up of oral cytotoxic agents and small-
molecule inhibitors (i.e. targeted therapy)
• Standard chemotherapy is generally cytotoxic 
while newer, targeted therapies are often 
cytostatic
J Natl Compr Canc Netw 2008;6(3):S1-15.; Image Courtesy of Labroots.com
Question 1
Image courtesy of cancernetwork.com
Drug Delivery
J Natl Compr Canc Netw 2008;6(3):S1-15.
Parenteral Oral
Consistent absorption Variable absorption
Maximally tolerated single dose Low daily maintenance dose
Tumor cells killed during single 
administration
Tumor cells continuously exposed
Requires bone marrow recovery 
period
Does not require bone marrow 
recovery period
Limited number of cycles Indefinite treatment length
Misconceptions
J Natl Compr Canc Netw 2008;6(3):S1-15.
Costs
Fed Pract 2016;33(1):22S-25S
• The cost of cancer care is the most rapidly increasing 







Standard for Oral 
Oncolytics
• Developed by the Hematology/Oncology 
Pharmacy Association (HOPA) for pharmacist’s 
involvement in oral oncolytic management
Pharmacy Practice 
Standard
J Oncol Pract 2019;15:e346-55
Prescribing
J Oncol Pract 2019;15:e346-55
Education
J Oncol Pract 2019;15:e346-55
Dispensing/Distribution
J Oncol Pract 2019;15:e346-55
Monitoring: Symptom 
Management
J Oncol Pract 2019;15:e346-55
Monitoring: Adherence
• Imperative to maximize effectiveness
• Varies from 50% to 100%
• Barriers to adherence include:















(Brand Name) Indication Class
FDA 
Approval






Abemaciclib (Verzenio®) Breast cancer CDK inhibitor Sept 2017
Enasidenib (Idhifa®) Acute myeloid 
leukemia
IDH2 inhibitor Aug 2017
Neratinib (Nerlynx®) Breast cancer EGFR tyrosine 
kinase inhibitor
July 2017










Ribociclib (Kisqali®) Breast cancer CDK inhibitor Mar 2017
Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA 2019
New Oncolytics: 2018
Generic Name 
(Brand Name) Indication Class
FDA 
Approval





Larotrectini (Vitrakvi®) Solid tumors TRK inhibitor Nov 2018





Lorlatinib (Lorbrena®) Non-small cell lung 
cancer
ALK tyrosine kinase 
inhibitor
Nov 2018
Talazoparib (TalzennaTM) Breast cancer PARP inhibitor Oct 2018





Duvelisib (Copiktra®) Chronic lymphocytic 
leukemia; follicular 
lymphoma
PI3K inhibitor Sept 2018
Encorafenib (Braftovi®) Melanoma BRAF kinase 
inhibitor
June 2018
Binimetinib (Mektovi®) Melanoma MEK inhibitor June 2018
Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA 2019
New Oncolytics: 2019
Generic Name 
(Brand Name) Indication Class
FDA 
Approval
Zanubrutinib (BrukinsaTM) Mantle cell 
lymphoma
BTK tyrosine kinase 
inhibitor
Nov 2019
Fedratinib (Inrebic®) Myelofibrosis FLT3 tyrosine kinase 
inhibitor
Aug 2019
Entrectinib (RozlytrekTM) Non-small cell 
lung cancer
TRK inhibitor Aug 2019





Darolutamide (Nubeqa®) Prostate cancer Antiandrogen July 2019
Selinexor (XpovioTM) Multiple myeloma Nuclear export 
inhibitor
July 2019
Alpelisib (Piqray®) Breast cancer PI3K inhibitor May 2019
Erdafitinib (BalversaTM) Urothelial 
carcinoma
FGFR inhibitor Apr 2019
Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA 2019
ALK Inhibitors
Images courtesy of empr.com and thesocialmedwork.com
Brigatinib (Alunbrig®)
Alunbrig (brigatinib) [package insert]
Brigatinib (Alunbrig®)
Alunbrig (brigatinib) [package insert]
Lorlatinib (Lorbrena®)
Lorbrena (lorlatinib) [package insert]
BRAF Inhibitors
Image courtesy of empr.com
Encorafenib (Braftovi®)
Braftovi (encorafenib) [package insert]
MEK Inhibitors
Image courtesy of fiercebiotech.com
Binimetinib (Mektovi®)
Binimetinib (Mektovi) [package insert]
BTK Inhibitors
Image courtesy of fiercepharma.com
Zanubrutinib (BrukinsaTM)
Brukinsa (zanubrutinib) [package insert]
CDK Inhibitors
Images courtesy of en.50bestpharma.com and clinicaltrialsarena.com
Abemaciclib (Verzenio®)
Verzenio (abemaciclib) [package insert]
Ribociclib (Kisqali®)
Kisqali (ribociclib) [package insert]
FLT3 Inhibitors
Images courtesy of clinicaltrialsarena.com and hcp.novartis.com
Gilteritinib (Xospata®)
Xospata (gilteritinib) package insert]
Midostaurin (Rydapt®)
Rydapt (midostaurin) package insert]
FGFR Inhibitor
Image courtesy of empr.com
Erdafitinib (Balversa®)
Balversa (erdafitinib) package insert]
IDH2 Inhibitor
Image courtesy of cancerhealth.com
Enasidenib (Idhifa®)
Idhifa (enasidenib) [package insert]
PI3K Inhibitors
Image courtesy of hcp.novartis.com and empr.com
Alpelisib (Piqray®)
Piqray (alpelisib) [package insert]; Image courtesy of healthcentral.com
Duvelisib (Copiktra®)
Copiktra (duvelisib) [package insert]
TRK Inhibitors
Images courtesy of empr.com
Entrectinib (Rozlytrek®)
Rozlytrek (entrectinib) [package insert]
Larotrectinib (Vitrakvi®)

















Boca Raton Regional Hospital
Baptist Health South Florida
EOsmon@BRRH.com
References
1. NCI Dictionary of Cancer Terms. National Cancer Institute. 
https://www.cancer.gov/publications/dictionaries/cancer-terms. Published 2019. 
Accessed December 31, 2019.
2. Weingart SN, Brown E, Bach PB, et al: NCCN task force report: Oral chemotherapy. 
J Natl Compr Canc Netw 2008;6(3):S1-15.
3. Dahl BJ. The cost of oncology drugs: A pharmacy perspective, part I. Fed Pract
2016;33(1):22S-25S.
4. Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology/oncology pharmacist 
association best practices for the management of oral oncolytic therapy: Pharmacy 
practice standard. J Oncol Pract 2019;15:e346-55. 
5. Kinase Inhibitors for Cancer Treatment. Chemoth.com. 
https://chemoth.com/types/kinaseinhibitors. Published 2020. Accessed January 5, 
2020.
6. Hematology/Oncology (Cancer) Approvals & Safety Notifications. U.S. Food and 
Drug Administration. https://www.fda.gov/drugs/resources-information-approved-
drugs/hematologyoncology-cancer-approvals-safety-notifications. Published 2019. 
Accessed December 30, 2019.
7. Alunbrig (brigatinib) [package insert]. Cambridge, MA:ARIAD Pharmaceuticals, 
Inc.;2017.
8. Lorbrena (lorlatinib) [package insert]. New York, NY: Pfizer Inc,;2018.
9. Braftovi (encorafenib) [package insert]. Boulder, CO: Array BioPharma Inc.;2018.
10. Binimetinib (Mektovi) [package insert]. Boulder, CO: Array BioPharma Inc.;2018.
References
11. Brukinsa (zanubrutinib) [package insert]. San Mateo, CA: BeiGene, Ltd.;2019.
12. Verzenio (abemaciclib) [package insert]. Indianapolis, IN: Lilly USA, LLC;2017.
13. Kisqali (ribociclib) [package insert]. East Hanover, NJ: Novartis;2017.
14. Xospata (gilteritinib) package insert]. Northbrook, IL: Astellas Pharma US, 
Inc.;2018.
15. Rydapt (midostaurin) package insert]. East Hanover, NJ: Novartis;2017.
16. Balversa (erdafitinib) package insert]. Horsham, PA: Janssen Products, LP;2019.
17. Idhifa (enasidenib) [package insert]. Cambridge, MA: Agios Pharmaceuticals;2019.
18. Piqray (alpelisib) [package insert]. East Hanover, NJ: Novartis;2019.
19. Copiktra (duvelisib) [package insert]. Needham, MA: Verastem, Inc.;2018.
20. Rozlytrek (entrectinib) [package insert]. South San Francisco, CA: Genentech USA, 
Inc.;2019.
21. Vitrakvi (larotrectinib) [package insert]. Whippany, NJ: Bayer HealthCare 
Pharmaceuticals Inc.;2018.
